Cristina Granetto

Via A. Carle 25
Cuneo, 12100, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 26 publications

The prognostic value of radiomic features in liver-limited metastatic colorectal cancer patients from the TRIBE2 study.

The prognostic value of radiomic features in liver-limited metastatic colorectal cancer patients from the TRIBE2 study.

Journal: Future oncology (London, England)

Published: August 14, 2023

Initial Panitumumab Plus Fluorouracil, Leucovorin, and Oxaliplatin or Plus Fluorouracil and Leucovorin in Elderly Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The PANDA Trial by the GONO Foundation.

Initial Panitumumab Plus Fluorouracil, Leucovorin, and Oxaliplatin or Plus Fluorouracil and Leucovorin in Elderly Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The PANDA Trial by the GONO Foundation.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: August 03, 2023

Baseline Cytokine Profile Identifies a Favorable Outcome in a Subgroup of Colorectal Cancer Patients Treated with Regorafenib.

Baseline Cytokine Profile Identifies a Favorable Outcome in a Subgroup of Colorectal Cancer Patients Treated with Regorafenib.

Journal: Vaccines

Published: December 22, 2022

TremelImumab and Durvalumab Combination for the Non-OperatIve Management (NOM) of Microsatellite InstabiliTY (MSI)-High Resectable Gastric or Gastroesophageal Junction Cancer: The Multicentre, Single-Arm, Multi-Cohort, Phase II INFINITY Study.

TremelImumab and Durvalumab Combination for the Non-OperatIve Management (NOM) of Microsatellite InstabiliTY (MSI)-High Resectable Gastric or Gastroesophageal Junction Cancer: The Multicentre, Single-Arm, Multi-Cohort, Phase II INFINITY Study.

Journal: Cancers

Published: May 13, 2021

Unusual Fatal Outcome Following Administration of a Combination of anti-PD1 and anti-CTLA4 in Metastatic Renal Cell Carcinoma: Liver Toxicity Case Report and a Literature Review.

Unusual Fatal Outcome Following Administration of a Combination of anti-PD1 and anti-CTLA4 in Metastatic Renal Cell Carcinoma: Liver Toxicity Case Report and a Literature Review.

Journal: European journal of case reports in internal medicine

Published: May 13, 2021

Exploring clinical and gene expression markers of benefit from FOLFOXIRI/bevacizumab in patients with BRAF-mutated metastatic colorectal cancer: Subgroup analyses of the TRIBE2 study.

Exploring clinical and gene expression markers of benefit from FOLFOXIRI/bevacizumab in patients with BRAF-mutated metastatic colorectal cancer: Subgroup analyses of the TRIBE2 study.

Journal: European journal of cancer (Oxford, England : 1990)

Published: February 24, 2021

Cytokine Profiling of End Stage Cancer Patients Treated with Immunotherapy.

Cytokine Profiling of End Stage Cancer Patients Treated with Immunotherapy.

Journal: Vaccines

Published: February 23, 2021

Treating patients with cancer amidst the COVID-19 pandemic: experience of a regional hospital in the Piedmont region in northern Italy.

Treating patients with cancer amidst the COVID-19 pandemic: experience of a regional hospital in the Piedmont region in northern Italy.

Journal: Tumori

Published: July 25, 2020

Circulating cytokines and outcome in metastatic colorectal cancer patients treated with regorafenib.

Circulating cytokines and outcome in metastatic colorectal cancer patients treated with regorafenib.

Journal: World journal of gastrointestinal oncology

Published: November 14, 2019

Erratum to "Lung cancer" [Crit. Rev. Oncol./Hematol. 27 (February (2)) (1998) 133-134].

Erratum to "Lung cancer" [Crit. Rev. Oncol./Hematol. 27 (February (2)) (1998) 133-134].

Journal: Critical reviews in oncology/hematology

Published: November 07, 2019

Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial.

Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial.

Journal: The Lancet. Oncology

Published: November 05, 2019

Italian survey on cetuximab-based therapy of elderly patients with metastatic colorectal cancer.

Italian survey on cetuximab-based therapy of elderly patients with metastatic colorectal cancer.

Journal: Cancer chemotherapy and pharmacology

Published: May 14, 2019

Showing 1-12 of 26

Last Updated: 09/26/2026